
SiteMinder (ASX: SDR) 1H FY25 Half-Year Results Analysis
The company is still growing revenue but free cash flow generation and profit margins are tracking below expectations.
The company is still growing revenue but free cash flow generation and profit margins are tracking below expectations.
AUB Group (ASX: AUB) boasts a resilient business model and an excellent track record of dividend growth over the long term.
The long term thesis remains on track and the current share price weakness looks like a potential opportunity to me.
3 reasons I will sell my shares in AF Legal after considering the half-year report.
Dicker Data (ASX: DDR) showed a strong profitability improvement in the second half of its CY 2024 reporting year.
Monash IVF (ASX: MVF) shifts from acquisitions to organic growth, eyeing Victoria’s recovery, global expansion, and cost efficiencies to drive future gains.
The KME H1 FY 2025 results showed modest revenue growth, improved profit, and a strengthening balance sheet.
Doctors love Polynovo’s Novosorb BTM and Novosorb MTX products, but the market hated its H1 FY 2025 results.
The Energy One (ASX: EOL) share price has reacted strongly to its return to profitability in H1 FY 2025.
IPD Group (ASX: IPG) reported decent results and the IPD Group share price has moved up slightly, despite weak commercial construction.
Solid results from a company that just keeps on delivering growth.
Netwealth (ASX: NWL) posts record inflows, hitting $101.6B FUA. Can it sustain momentum as legacy platforms decline?
I will be keeping an eye on the PharmX (ASX: PHX) share price because the PharmX business model seems to have the potential to scale nicely.
Growth Gauge has long followed Audinate shares, and is expecting more optimism in the future, after the undeniably tough H1 FY 2025 results were released.
The BSA Ltd share price fell 83% yesterday.
It’s easy to tell the H1 FY 2024 Hub24 (ASX: HUB) results were good. But I’m less confident that there is still value on offer after the stock has doubled in price.
Chris Coe explains why he recently bought some share in this little known dividend stock with a P/E ratio around 9.
The Fiducian Group share price gained around 10% in response to some fairly solid H1 FY 2025 results.
Adore Beauty (ASX: ABY) reports strong margin expansion in H1 FY25, but revenue growth remains weak. With 25+ stores planned, can its shift to physical retail drive long-term gains? Read more.
The Pro Medicus (ASX: PME) share price was down slightly in response to the very strong Pro Medicus H1 FY 2025 results.